Press release
Ectonucleotide Pyrophosphatase/Autotaxin Pipeline Review Studied and Analyzed in New Business Study
Strategic Acquisitions Expected to Accelerate Drug Development in Autotaxin Diseases
Pharmaceutical giant, Eli Lilly has concluded a major acquisition to extend its pipeline of cancer treatment triggered by autotaxin. ARMO BioSciences Inc. is a promising drug manufacturer for cancer and its keen on producing relevant drugs that activates the immune system to combat cancers. Such business transactions enhance the prospects of ectonucleotide pyrophosphatase/phosphodiesterase family member 2 therapeutics market.
Click here for Free Sample Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=1798325
Further, Biopharmaceutical manufacturers are integrating resources to achieve new heights in ectonucleotide pyrophosphatase/phosphodiesterase family member 2 therapeutics market. Several clinical researches are in different phases to achieve success in complete therapeutics for autotaxin induced diseases.In its endeavor to introduce novel medicines in fibrosis and inflammation, besides other indications, clinical stage Biotechnology Company, Galapagos NV has confirmed its discovery of selective autotaxin inhibitor, GLPG-1690 to treat idiopathic pulmonary (IPF) disease. This discovery is expected to pave the way for novelties in ectonucleotide pyrophosphatase/phosphodiesterase family member 2 therapeutics market. In its phase II study of IPF patients, Galapagos NV confirmed control in disease progression with the aid of GLPG-1690 a proprietary product of Galapagos NV, granted orphan status in Europe and the US.In addition, Biopharmaceutical Company, PharmAkea has successfully carried out phase 1 of its clinical research on IPF. The trial outlaid the effectiveness of PAT-1251 as a probable treatment for IPF. The discovery is a landmark achievement in ectonucleotide pyrophosphatase/phosphodiesterase family member 2 therapeutics market. Exhaustive research outcomes entailed in the report presents the strategies harnessed by companies and their effect on the growth of ectonucleotide pyrophosphatase/phosphodiesterase family member 2 therapeutics market. This section of the report also enlists the segments present in the market which include, therapeutics development and therapeutics assessment. Based on therapeutics development, the ectonucleotide pyrophosphatase/phosphodiesterase family member 2 therapeutics market is sectioned as stage of development, therapy area, and indication. Based on therapeutics assessment, the autotaxin therapeutics market is bifurcated as mechanism of action, route of administration, and molecule type. On the basis of insights outlaid in the report, readers can assess the impact of segments on the growth of the market, and also identify the strategies that reflect positively on revenue generation. The report also provides holistic research outputs on the highest revenue generating segment in ectonucleotide pyrophosphatase/phosphodiesterase family member 2 therapeutics market enabling readers to devise effective investment plans.
Browse Full Report with TOC@ https://www.marketresearchhub.com/report/ectonucleotide-pyrophosphatasephosphodiesterase-family-member-2-autotaxin-or-extracellular-lysophospholipase-d-or-enpp2-or-ec-31439-pipeline-review-h1-2018-report.html
Key Players Identified in Autotaxin Therapeutics Market
Exhaustive data compiled in the report offers key insights on the profit driving strategies formulated by key players in ectonucleotide pyrophosphatase/phosphodiesterase family member 2 therapeutics market. New entrants as well as existing players can decipher the influence of these strategies on the purchase decisions of end-users and implement similar growth driven marketing strategies. Leading players identified in the report are Eli Lilly and Co, Galapagos NV, LegoChem Biosciences Inc, Ono Pharmaceutical Co Ltd, Ribomic Inc, TaiwanJ Pharmaceuticals Co Ltd, and X-Rx Inc.
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like pharmaceutical market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free: 800-998-4852 (US-Canada)
Email: press@marketresearchhub.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ectonucleotide Pyrophosphatase/Autotaxin Pipeline Review Studied and Analyzed in New Business Study here
News-ID: 1089527 • Views: …
More Releases from Market Research Hub
Acrylate Polymers Market Share, Industry Analysis & Forecast Report 2019-2025
Market Research Hub (MRH) has actively uploaded a smart research report titled “Global Acrylate Polymers Market Professional Survey Report 2019”, to its broad online database. The primary motive of this study is to impart vital details associated to development of the Acrylate Polymers Market. The assessment includes brief knowledge about market size, Y-o-Y growth, market dynamics and competitive scenario expected to transform in the near future. Ever section of the…
Abrasive Wheels & Discs Market Drivers, Segment by Regions and Growth Analysis, …
Market Research Hub (MRH) has recently uploaded a new study titled “Global Abrasive Wheels & Discs Market Professional Survey Report 2019” to its broad online storehouse. The global Abrasive Wheels & Discs Market conveniently covers prime factors motivating development and steering industry trends and demand scenarios. Readers can easily quantify market opportunities with the availability of information such as market sizing and market forecasting, thereby being able to analyze the…
Oral Dosing Cups Market Analysis By Application 2025 | Top Players- Comar, Inc, …
Market Research Hub (MRH) has actively uploaded a smart research report titled “Global Oral Dosing Cups Market Insights, Forecast to 2025”, to its broad online database. The primary motive of this study is to impart vital details associated to development of the Oral Dosing Cups market. The assessment includes brief knowledge about market size, Y-o-Y growth, market dynamics and competitive scenario expected to transform in the near future. Ever section…
Opthalmic Lenses Market 2019-2025|Major Players- ZEISS, HOYA, SHIMIZU, Rodenstoc …
Market Research Hub (MRH) has actively uploaded a smart research report titled “Global Opthalmic Lenses Market Insights, Forecast to 2025”, to its broad online database. The primary motive of this study is to impart vital details associated to development of the Opthalmic Lenses market*. The assessment includes brief knowledge about market size, Y-o-Y growth, market dynamics and competitive scenario expected to transform in the near future. Ever section of the…
More Releases for Autotaxin
Idiopathic Pulmonary Fibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Idiopathic Pulmonary Fibrosis pipeline constitutes 80+ key companies continuously working towards developing 100+ Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Idiopathic Pulmonary Fibrosis Treatment Market Size Projected To Reach USD 13.84 …
The global demand for the Idiopathic Pulmonary Fibrosis treatment market is projected to experience substantial growth, reaching an estimated market size of approximately USD 13.84 billion by 2032. This represents a significant increase from the USD 4.54 billion recorded in 2023, reflecting a robust compound annual growth rate (CAGR) of 13.18% during the study period from 2024 to 2032. The anticipated expansion is driven by several factors, including the rising…
Idiopathic Pulmonary Fibrosis Treatment Market Size Worth USD 8.3 Billion in 203 …
The global Idiopathic Pulmonary Fibrosis (IDF) treatment market size was USD 3.51 Billion in 2022 and is expected to register a rapid revenue CAGR of 6.2% during the forecast period. The global Idiopathic Pulmonary Fibrosis (IPF) treatment market is experiencing significant growth driven by increasing research and development (R&D) activities and rapid technological advancements, according to a recent market research report.
Key factors propelling market revenue growth include the development of…
The Pulmonary Fibrosis Treatment Market to witness an influx of robotic surgerie …
Monotherapy is cost-effective and gives deliverable action directly to the site of action in a few minutes, and is said to be a safe and effective method for treating idiopathic pulmonary fibrosis (IPF). According to Persistence Market Research (PMR), request for pulmonary fibrosis treatment is predicted to increase, enabling the market to surpass US$ 2.7 Bn by 2021. Over the coming years, rising cases of IPF will support the expansion…
United States Idiopathic Pulmonary Fibrosis Treatment Market Growth and Forecast …
According to the latest report by IMARC Group, titled, "United States Idiopathic Pulmonary Fibrosis Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027", The United States idiopathic pulmonary fibrosis treatment market is expected to exhibit a CAGR of 7.30% during 2022-2027.
Idiopathic pulmonary fibrosis (IPF) refers to an interstitial lung disease that causes a buildup of scar tissues in the lungs. It is diagnosed via blood tests, chest imaging…
Europe Idiopathic Pulmonary Fibrosis Treatment Market 2022-2027: Trends, Growth, …
According to the latest report by IMARC Group, titled, "Europe Idiopathic Pulmonary Fibrosis Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027", The Europe idiopathic pulmonary fibrosis treatment market is expected to exhibit a CAGR of 8.00% during 2022-2027.
Idiopathic pulmonary fibrosis (IPF) refers to the progressive and irreversible fibrosing interstitial pneumonia that directly impacts the functioning of the lungs. It is generally characterized by the formation of scar…
